New data on chronic venous disease: a new place for Cyclo 3 ® Fort.

New data on chronic venous disease: a new place for Cyclo 3® Fort. Int Angiol. 2017 Oct 23;: Authors: Kakkos SK, Bouskela E, Jawien A, Nicolaides AN Abstract With our increasing knowledge of the epidemiology, pathophysiology, investigation and clinical aspects of chronic venous disease (CVD) and new data on the various therapies available, an update of the recommendations on CVD and its management appears to be necessary. The symposium "New Data on Chronic Venous Disease, New Place for Cyclo 3® Fort", held at the annual meeting of the European Venous Forum (EVF) on June 30th, 2017 in Porto, Portugal, reported the recent developments on Ruscus+HMC+Vit C (Cyclo 3® Fort), including the results of a series of in vivo pharmacological experiments and a recent meta-analysis. Additionally, the symposium provided first-hand information on the process, rules, main findings, and expected contents of the prospective 2018 CVD guidelines. Analysis of the evidence showed that the effect of Ruscus+HMC+Vit C on pain, heaviness, feeling of swelling, tingling, ankle circumference and global symptoms score reached Grade A. Therefore, the new guidelines should specify that Ruscus+HMC+Vit C merits a Grade 1A recommendation. PMID: 29063748 [PubMed - as supplied by publisher]
Source: International Angiology - Category: Cardiology Tags: Int Angiol Source Type: research